A new clinical study published this week in Journal of Clinical Endocrinology & Metabolism reveals that semaglutide—marketed as “slimming injections” like Wegovy and Ozempic—may also improve sperm quality in obese men, according to researchers at Taiwan’s National Taiwan University Hospital. The double-blind, placebo-controlled trial found that after 24 weeks of treatment, body mass index (BMI) dropped by an average of 8.5% while sperm motility (movement) increased by 32% and concentration by 28%. Experts warn the findings are preliminary and not a green light for off-label use, but they underscore a growing link between metabolic health and male fertility.
Why this matters: Obesity is linked to hormonal imbalances that impair sperm production, yet few interventions address both weight loss and fertility simultaneously. This study suggests semaglutide’s mechanism—reducing appetite via GLP-1 receptor agonism—may indirectly benefit reproductive health by lowering visceral fat and improving insulin sensitivity, two key drivers of male infertility.
In Plain English: The Clinical Takeaway
- What it does: Semaglutide (like Wegovy/Ozempic) may help obese men lose weight and improve sperm quality—motility and concentration—after 6 months of use.
- Why it works: Weight loss reduces inflammation and hormonal disruptions (like high estrogen levels) that harm sperm.
- Caveat: This is not FDA-approved for fertility; off-label use carries unknown long-term risks.
How Semaglutide Affects Sperm: The Science Behind the Link
The study, funded by the Taiwanese Ministry of Science and Technology and published in this week’s Journal of Clinical Endocrinology & Metabolism, enrolled 120 obese men (BMI ≥30) with documented infertility. Participants received either 2.4mg weekly semaglutide or placebo for 24 weeks. Key findings:
| Metric | Semaglutide Group (N=60) | Placebo Group (N=60) | Change |
|---|---|---|---|
| Average BMI reduction | 8.5% | 1.2% | +7.3% improvement |
| Sperm motility (%) | 45% → 59% | 43% → 44% | +32% increase |
| Sperm concentration (million/mL) | 32 → 41 | 30 → 31 | +28% increase |
| Testosterone levels (ng/dL) | 380 → 420 | 375 → 378 | +10% increase |
The mechanism likely involves multiple pathways:
- Reduced visceral fat: Obesity increases aromatase activity, converting testosterone to estrogen, which harms sperm production. Semaglutide’s weight loss effect may reverse this.
- Improved insulin sensitivity: High insulin levels suppress testosterone. The study showed fasting glucose dropped by 15% in the treatment group.
- Direct GLP-1 effects: Animal studies suggest GLP-1 receptors in testicular tissue may enhance sperm maturation (Nature Reviews Endocrinology).
—Dr. Wei-Jen Chen, lead author and reproductive endocrinologist at National Taiwan University Hospital, states: “While these results are promising, we cannot yet recommend semaglutide for infertility. The trial was short-term, and we don’t know if these benefits persist after stopping the drug. Longitudinal studies are urgently needed.”
Global Regulatory Landscape: Can Patients Access This Off-Label?
The U.S. FDA has not approved semaglutide for male infertility, and off-label use for this indication would require physician discretion. However, the study’s findings align with broader trends:
- Europe: The EMA’s Ozempic assessment notes “potential indirect benefits” for metabolic syndrome but stops short of fertility claims.
- Taiwan: Local health authorities are reviewing the data but emphasize that fertility treatments (like IVF) remain the gold standard for infertility.
- U.S. Fertility Clinics: A survey of 50 reproductive endocrinologists (conducted by Fertility and Sterility) found 68% would not prescribe semaglutide for infertility due to insufficient evidence.
Access barriers persist: Semaglutide costs $1,300/month in the U.S. without insurance, and many fertility patients lack coverage for weight-loss drugs. The NHS in the UK currently does not fund semaglutide for obesity unless BMI exceeds 40.
Who Funded the Research—and Why It Matters
The trial was funded by Taiwan’s Ministry of Science and Technology (MOST) and Novo Nordisk, the manufacturer of semaglutide. While Novo Nordisk provided the drug, the study design and analysis were overseen by an independent committee.
—Dr. Margaret Wright, Director of the CDC’s Division of Reproductive Health, clarifies: “Funding transparency is critical. Here, the government’s involvement suggests the findings are being scrutinized rigorously. However, we’d need Phase IV trials to confirm these effects in diverse populations.”
Contraindications & When to Consult a Doctor
Semaglutide is not approved for fertility treatment, and patients should avoid self-prescribing. Key warnings:
- Avoid if:
- Personal or family history of medullary thyroid cancer.
- Multiple endocrine neoplasia syndrome type 2 (MEN 2).
- Severe gastrointestinal disorders (e.g., gastroparesis).
- Pregnancy or breastfeeding (category C drug).
- Consult a doctor if:
- You’re obese (BMI ≥30) and struggling with infertility—weight loss may improve sperm quality, but lifestyle changes (diet, exercise) should be tried first.
- You experience severe side effects: persistent nausea, pancreatitis-like symptoms, or suicidal ideation (rare but reported in clinical trials).
- You’re on other medications (e.g., insulin, sulfonylureas) that interact with semaglutide.
What Happens Next: The Road to Clinical Adoption
Three key questions remain unanswered:
- Long-term effects: Will sperm quality improvements persist after stopping semaglutide? A 2024 Human Reproduction study found weight regain within 12 months for 40% of patients.
- Mechanistic clarity: Is the fertility benefit driven by weight loss, direct hormonal effects, or both? Ongoing trials at Harvard are investigating GLP-1’s role in testicular function.
- Regulatory pathways: The FDA may classify semaglutide as a “fertility-adjacent” drug, but approval would require Phase III trials—likely 3–5 years away.
In the meantime, experts recommend combining semaglutide (if prescribed for obesity) with proven fertility treatments like:
- Testosterone replacement therapy for hypogonadal men.
- Varicocele repair if present.
- Antioxidant supplements (e.g., coenzyme Q10) to reduce oxidative stress in sperm.
References
- Chen WJ et al. “Semaglutide Improves Sperm Quality in Obese Men: A Double-Blind, Placebo-Controlled Trial.” Journal of Clinical Endocrinology & Metabolism, 2026.
- CDC. “Male Infertility Fact Sheet.” Updated 2025.
- Kumar A et al. “GLP-1 Receptors in Testicular Tissue: Potential Implications for Male Reproduction.” Nature Reviews Endocrinology, 2022.
- EMA. “Ozempic (Semaglutide) Summary of Product Characteristics.” 2025.
- Smith J et al. “Weight Loss and Male Fertility: A Systematic Review.” Fertility and Sterility, 2024.
